BAE Systems Helps Ireland Lead the Way With First Plug-In Electric Hybrid Propulsion Systems on Public Buses
10.12.2020 17:00:00 EET | Business Wire | Press release
BAE Systems, a world leader in electric propulsion, has delivered the first plug-in capable electric hybrid propulsion systems to Alexander Dennis Limited who are supplying new buses to Ireland. The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005589/en/
The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year. (Photo: Alexander Dennis Limited)
The Series-ER system builds on the company’s more than 20 years of innovation and proven technology and powers more than 13,000 buses around the world. That technology is on buses in service throughout Europe, including cities such as Brighton, London, Namur, and Paris. The Irish buses are the first in the world to benefit from the company’s new plug-in technology.
This means that as well as using the efficient onboard generator to charge itself while the bus is on the move, the buses can now also plug into the grid for power, giving operators another way to recharge their buses.
The Series-ER system enables buses to run for up to five kilometers (three miles) at a time with the engine turned off. This capability provides towns and cities with a new opportunity to improve air quality. The buses will use up to 35 percent less fuel when compared to a conventional bus.
“Clean transportation technology in our cities is critical to reach a zero emission future,” said Ian Wilson, director of business development for Power & Propulsion Solutions at BAE Systems. “Our system will help Ireland take the next step towards full electrification and improve the air quality where people live, work and visit.”
“The Alexander Dennis Enviro400ER is ideally suited for flexible operating needs including zero-emission running at air pollution hotspots,” said Paul Davies president and managing director at ADL. “With the ability to externally charge the batteries, the use of on-board power generation can be further reduced. This new generation of double deck buses for Ireland once again demonstrates that with ADL’s focus on innovation, we are building the buses our cities need to solve their transport challenges.”
The bus propulsion system includes a highly efficient electric motor and generator, an enhanced battery, and smart electronic controls to create a clean form of electric drive propulsion for the buses. It allows operators to take advantage of green grid power, and sets them up for full electric operation in the future. Operators can now use the grid for power – much like an all-electric bus – and add more battery capacity to increase their engine off time. In many instances this will mean an entire route can operate on grid power when the necessary charging infrastructure is in place.
BAE Systems develops and services its technology at its facilities in Endicott, New York, and Rochester, UK.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005589/en/
Contact information
Anthony DeAngelis, BAE Systems
Mobile: +1 603-714-3664
anthony.deangelis@baesystems.com
www.baesystems.com/US
@BAESystemsInc
Sean Hills, BAE Systems
Mobile: +447827 991666
sean.hills3@baesystems.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
